Ani Pharmaceuticals Inc. (ANIP) intrinsic value & 10-year financials

Ani Pharmaceuticals Inc. (ANIP) has a Graham intrinsic value of $110.28 per share. At $72.29 on Oct 17, 2026, the stock trades 34% below that value. Over the last 10 fiscal years revenue grew 23.9% a year to $883.4M, with an average return on invested capital of 4.2%.

Graham intrinsic value
$110.28
Share price (Oct 17, 2026)
$72.29
Price vs Graham value
34% below
Market cap
$1.5B
Revenue (FY2025)
$883.4M
Revenue growth (10-yr CAGR)
23.9%
ROIC (10-yr avg)
4.2%
Free cash flow (FY2025)
$171.4M

ANIP 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $883.4M $78.3M $3.32 $171.4M 12.6% 15.7%
FY2024 $614.4M -$18.5M -$1.04 $47.8M 0.1% 0.1%
FY2023 $486.8M $18.8M $0.85 $110.1M 9.6% 8.4%
FY2022 $316.4M -$47.9M -$3.05 -$40.1M -11.2% -5.0%
FY2021 $216.1M -$42.6M -$3.40 $765.0K -18.4% -6.8%
FY2020 $208.5M -$22.5M -$1.88 $9.1M -7.7% -3.9%
FY2019 $206.5M $6.1M $0.50 $39.0M 7.9% 5.8%
FY2018 $201.6M $15.5M $1.30 $61.3M 17.5% 12.4%
FY2017 $176.8M -$1.1M -$0.09 $29.1M 16.0% 7.9%
FY2016 $128.6M $3.9M $0.34 $22.9M 15.6% 7.1%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

ANI PHARMACEUTICALS INC is a consistent compounder, expanding top-line revenue at 23.9% annually over the past decade.

ANI PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just 4.2% ROIC.

Over the decade, ANI PHARMACEUTICALS INC shows that the company has leveraged its balance sheet to sustain operations.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, ANI PHARMACEUTICALS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $110.28 per share.

ANIP stock: frequently asked questions

What is the intrinsic value of Ani Pharmaceuticals Inc. (ANIP) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, ANIP's intrinsic value is about $110.28 per share.

Is ANIP stock undervalued?

At $72.29 (close on Oct 17, 2026), ANIP trades 34% below its Graham value of $110.28. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Ani Pharmaceuticals Inc. grown?

Revenue went from $128.6M in fiscal 2016 to $883.4M in fiscal 2025, a compound annual growth rate of 23.9%. Net income was $78.3M in fiscal 2025.

Does Ani Pharmaceuticals Inc. generate free cash flow?

Ani Pharmaceuticals Inc. generated $171.4M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 9 of the last 10 reported years.

What is ANIP's return on invested capital?

Average ROIC over the last 10 fiscal years was 4.2%, and average return on equity was -1.2%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this ANIP data come from?

From Ani Pharmaceuticals Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Aug 7, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks